Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease, N Engl J Med, vol.375, pp.1946-1960, 2016. ,
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience, Aliment Pharmacol Ther, vol.47, pp.588-595, 2018. ,
Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Realworld Experience from a Multicenter Cohort Study, Inflamm Bowel Dis, vol.23, pp.833-839, 2017. ,
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort, Aliment Pharmacol Ther, vol.45, pp.1232-1243, 2017. ,
Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases, Am J Gastroenterol, vol.109, pp.1250-1256, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01688079
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment, J Crohn's Colitis, vol.1, pp.4-22, 2020. ,
Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge, J Crohns Colitis, vol.10, pp.1096-102, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01662135
Two Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks, Inflamm Bowel Dis, vol.26, p.7, 2020. ,
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease, Clin Gastroenterol Hepatol, issue.20, pp.30205-30211, 2020. ,
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study, J Crohns Colitis, vol.14, pp.33-45, 2020. ,
How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?, Clin Gastroenterol Hepatol, issue.19, pp.31092-31096, 2019. ,
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease, Gastroenterology, vol.153, pp.827-834, 2017. ,
Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response, J Crohns Colitis, p.162, 2019. ,
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease, Gastroenterology, vol.154, pp.1660-1671, 2018. ,
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates, J Crohns Colitis, vol.13, pp.864-872, 2019. ,
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease, Clin Gastroenterol Hepatol, vol.15, pp.1427-1434, 2017. ,